Collagen-targeting PET probe may improve diagnosis and treatment of pulmonary fibrosis

April 5, 2017, Massachusetts General Hospital
PET scans of mouse lungs with (right) and without (fibrosis) using a new imaging probe. Credit: P. Désogère et al., Science Translational Medicine (2017)

A PET imaging probe developed by Massachusetts General Hospital (MGH) investigators appears able to diagnose and stage pulmonary fibrosis—an often life-shortening lung disease—as well as monitor the response to treatment. In their paper published in Science Translational Medicine, the team reports how the collagen-targeting probe, called 68Ga-CBP8, bound to scar tissue in the lungs of two animal models in a way that indicated the extent of fibrosis and also detected reduced fibrosis in animals that received an anti-fibrotic drug. Experiments using human lung tissue suggested that the probe also could differentiate between stable disease and progressive fibrosis, information important to treatment planning.

"Increased collagen production is a hallmark of in the lungs and in other organs," explains Peter Caravan, PhD, of the Athinoula A. Martinos Center for Biomedical Imaging and co-director of the Institute for Innovation in Imaging at MGH, a co-corresponding author of the report. "High resolution CT scanning can precisely diagnose only 50 percent of and often cannot predict prognosis or show response to therapies, making invasive biopsy—which can be hazardous to these patients—the only definitive diagnostic method. Non-invasive PET imaging with 68Ga-CBP8 provides information on the entire without a biopsy, which would only reflect a small portion of the lung."

While may be caused by exposure to pollutants or result from other disease, in most cases the cause is unknown or idiopathic. The buildup of scar tissue stiffens the lungs, making breathing difficult and restricting the passage of oxygen into the blood. For most patients, the condition progressively worsens, leading to death in 3 to 5 years. Two drugs that slow the progression of have recently been approved by the FDA, and a definitive, noninvasive diagnostic method could enable earlier diagnosis and treatment and monitoring of treatment response.

A new PET probe reveals scarring from fibrosis in the lungs. Credit: Désogère et al.

The ability of PET technology to detect and quantify collagen molecules presents significant advantages over CT scanning, which only reveals structural abnormalities, which could be caused by other conditions. The MGH team's initial experiments showed that 68Ga-CBP8 specifically binds to collagen in a mouse model of pulmonary fibrosis but did not accumulate in the lungs of healthy animals.

Additional experiments in another model showed greater uptake of the in areas of more extensive fibrosis and the ability to track disease progression over time. The reduction in fibrosis resulting from treatment with an experimental antibody-based drug could clearly be tracked by a combination of 68Ga-CBP8 PET and CT scanning. Application of 68Ga-CBP8 to tissues removed from the lungs of pulmonary fibrosis patients prior to transplantation also showed greater probe accumulation in more heavily scarred areas, suggesting that the results in the mouse models would probably also be seen in human patients.

"The ability of molecular PET imaging with this probe to detect early-stage fibrosis would allow us to begin treatment when it would be most effective," says Michael Lanuti, MD, MGH Division of Thoracic Surgery, co-corresponding author of the Science Translational Medicine paper. "This probe may also be able to distinguish new, active fibrosis from stable disease, which would allow clinicians to better tailor therapy to individual patients. And since response to therapy is difficult to ascertain with high-resolution CT scanning, PET molecular imaging may be a more sensitive way to detect changes in active fibrosis."

The MGH team is preparing the documentation required to test 68Ga-CBP8 in patients and has received National Heart, Lung and Blood (NHLBI) funding for such a trial, which may begin later this year.

Explore further: Vaccine improves fibrosis in mouse model of idiopathic pulmonary fibrosis

More information: "Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aaf4696

Related Stories

Vaccine improves fibrosis in mouse model of idiopathic pulmonary fibrosis

April 7, 2016
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disease characterized by lung fibrosis and declining lung function. There are currently few effective treatments for IPF, and the median survival following diagnosis ...

Antibody is effective against radiation-induced pulmonary fibrosis

March 31, 2017
Radiation therapy is part of the treatment regimen for about two thirds of cancer patients today. Radiotherapy is well tolerated in most cases, but it can also lead to damage in healthy tissues that are also irradiated. One ...

World first trial of shark inspired drug

January 31, 2017
La Trobe University scientists are preparing to run a world-first clinical trial of a new drug inspired by shark antibodies. The drug, AD-114, is a human protein that is based on the shape of an antibody of a Wobbegong shark.

Study finds key regulator in pulmonary fibrosis

October 20, 2016
A Yale-led research team has identified an important enzyme that could lead to new therapies for a chronic fatal lung disease that affects hundreds of thousands in the United States each year.

Researchers discover link between aging, devastating lung disease

February 23, 2017
A Mayo Clinic study has shown evidence linking the biology of aging with idiopathic pulmonary fibrosis, a disease that impairs lung function and causes shortness of breath, fatigue, declining quality of life, and, ultimately, ...

Recommended for you

New blood test to detect liver damage in under an hour

May 24, 2018
A quick and robust blood test that can detect liver damage before symptoms appear has been designed and verified using clinical samples by a team from UCL and University of Massachusetts.

Selective neural connections can be reestablished in retina after injury, study finds

May 24, 2018
The brain's ability to form new neural connections, called neuroplasticity, is crucial to recovery from some types of brain injury, but this process is hard to study and remains poorly understood. A new study of neural circuit ...

Space-like gravity weakens biochemical signals in muscle formation

May 23, 2018
Astronauts go through many physiological changes during their time in spaceflight, including lower muscle mass and slower muscle development. Similar symptoms can occur in the muscles of people on Earth's surface, too. In ...

Eating at night, sleeping by day swiftly alters key blood proteins

May 21, 2018
Staying awake all night and sleeping all day for just a few days can disrupt levels and time of day patterns of more than 100 proteins in the blood, including those that influence blood sugar, energy metabolism, and immune ...

Hotter bodies fight infections and tumours better—researchers show how

May 21, 2018
The hotter our body temperature, the more our bodies speed up a key defence system that fights against tumours, wounds or infections, new research by a multidisciplinary team of mathematicians and biologists from the Universities ...

Deep space radiation treatment reboots brain's immune system

May 21, 2018
Planning a trip to Mars? You'll want to remember your anti-radiation pills.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.